<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20231008059650N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-10-31</date_registration>
      <primary_sponsor>Institute of Medical History, Islamic and Complementary Medicine Studies</primary_sponsor>
      <public_title>Evaluation of the effectiveness of a herbal product containing Rhus Coriaria L. (Sumac) and Pimpinella Anisum (Anise) in patients with Gastroesophageal Reflux compared to placebo</public_title>
      <acronym>GERD</acronym>
      <scientific_title>Evaluation of the effectiveness of a herbal product containing Rhus Coriaria L. (Sumac) and Pimpinella Anisum (Anise) in patients with Gastroesophageal Reflux compared to placebo: A double-blind Randomized Clinical Trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-11-06</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>70</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/73127</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Single, Purpose: Treatment, Randomization description: In this study, we will use the block randomization method and in this two-group clinical trial, we will have 4 blocks. For each person who enters the study, a code is obtained from the software and it is determined which group (intervention or control) it belongs to. We use specialized random Allocation concealment, this method is such that before the allocation of the individual, the allocated group is not known, in this way, by using non-transparent envelopes sealed with a random sequence, which in In this method, each of the random sequences created is recorded on a card and the cards are placed in the envelopes in order. In order to maintain the random sequence, the outer surface of the envelopes is numbered in the same order. Finally, the lids of the envelopes are glued and placed in a box. Blocking and preparation of envelopes is done by a person not involved in data sampling and analysis, in this way, the person who collects, the person who analyzes and the person who participates in the type of intervention received and what each person in They do not know about the placed group, Blinding description: Patients participating in the study and doctors or researchers do not know the type of control or intervention group.</study_design>
      <phase>3</phase>
      <hc_freetext>Gastroesophageal Reflux.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In the medicine group, we put 3 grams of medicine (1.5 grams of brown sumac and 1.5 grams of anise) as a mixture, divided into 6 capsules of 500 mg and 2 tablets are prescribed after each meal for 4 weeks. The drug is made by professors specializing in Iranian medicine in the traditional pharmacy laboratory of the Faculty of Iranian Medicine, Iran University of Medical Sciences. Intervention 2: Control group: Toasted bread flour in 500 mg capsules is prescribed 2 times after each meal for 4 weeks. The medicine is made by professors specializing in Iranian medicine in the traditional pharmaceutical laboratory of the Faculty of Iranian Medicine, Iran University of Medical Sciences.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Malihe zaman Momeniha</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Iranian Medicine, No 847, Behesht St. South Side of Shahr Park, Vahdat-e-Islami St., Hasan Abad Sq., Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1114733311</zip>
        <telephone>+98 21 5515 2191</telephone>
        <email>momenihamalihezaman@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Somayeh Mahroozade</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Iranian Medicine, No 847, Behesht St. South Side of Shahr Park, Vahdat-e-Islami St., Hasan Abad Sq., Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1114733311</zip>
        <telephone>+98 21 5515 2191</telephone>
        <email>Dr.mahroozade@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients who have gastroesophageal reflux symptoms at least once a week (Heartburn and Regurgitation)
Patients who do not complication from gastroesophageal reflux disease.
People who have been diagnosed with reflux disease and have not taken medicine in the last 2 weeks and want to start anti-reflux treatment again.</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with regular glucocorticoid intake
Pregnancy
Breastfeeding
The presence of signs and symptoms of danger in the patient's history, such as weight loss of more than 10% during the last three months
Patients with a history of Barrett's disease
History of esophageal, stomach, or intestinal cancer
Patients with coagulation disorders
Patients with acute peptic ulcer or its complications</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>K20-K31</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Diseases of oesophagus, stomach and duodenum</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In the medicine group, we put 3 grams of medicine (1.5 grams of brown sumac and 1.5 grams of anise) as a mixture, divided into 6 capsules of 500 mg and 2 tablets are prescribed after each meal for 4 weeks. The drug is made by professors specializing in Iranian medicine in the traditional pharmacy laboratory of the Faculty of Iranian Medicine, Iran University of Medical Sciences.</i_keyword>
      <i_keyword>Control group: Toasted bread flour in 500 mg capsules is prescribed 2 times after each meal for 4 weeks. The medicine is made by professors specializing in Iranian medicine in the traditional pharmaceutical laboratory of the Faculty of Iranian Medicine, Iran University of Medical Sciences.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity of heartburn based on (QOLRAD) (FSSG). Timepoint: Severity of Heartburn before the start of the intervention, 2 and 4 weeks after the start of the intervention;. Method of measurement: Severity of Heartburn based on (FSSG) frequency scale for the symptoms of GERD و (QOLRAD)  Quality Of Life in Reflux and Dyspepsia.</prim_outcome>
      <prim_outcome>Frequency of Heartburn based on (QOLRAD) (FSSG). Timepoint: Frequency of Heartburn before the intervention, 2 and 4 weeks after the intervention;. Method of measurement: Frequency of Heartburn based on (FSSG)  frequency scale for the symptoms of GERD و  (QOLRAD) Quality Of Life in Reflux and Dyspepsia.</prim_outcome>
      <prim_outcome>Severity of Regurgitation based on (QOLRAD) (FSSG). Timepoint: Severity of Regurgitation before the start of the intervention, 2 and 4 weeks after the start of the intervention;. Method of measurement: Severity of Regurgitation based on (FSSG) frequency scale for the symptoms of GERD و (QOLRAD)  Quality Of Life in Reflux and Dyspepsia.</prim_outcome>
      <prim_outcome>Frequency of Regurgitation based on (QOLRAD) (FSSG). Timepoint: Frequency of Regurgitation before the intervention, 2 and 4 weeks after the intervention;. Method of measurement: Frequency of Regurgitation based on (FSSG)  frequency scale for the symptoms of GERD و  (QOLRAD) Quality Of Life in Reflux and Dyspepsia.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Stomach temperament in terms of coldness, warmth, dryness and humidity. Timepoint: Before the start of the intervention and 4 weeks after the start of the intervention. Method of measurement: Stomach temperament questionnaires.</sec_outcome>
      <sec_outcome>Drug side effects. Timepoint: Week 2 and 4 after the intervention. Method of measurement: Medication side effects questionnaire.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Institute of Medical History, Islamic and Complementary Medicine Studies</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-10-07</approval_date>
        <contact_name>Ethics committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Iran University of Medical Sciences, Hemmat Highway Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
